This prospective, single-center treatment-withdrawal crossover study enrolled 10 patients on chronic peritoneal dialysis (PD) and uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg).
Following written informed consent, participants entered the treatment arm, receiving oral hydrochlorothiazide once daily on top of their standard of treatment for 90 days. This was followed by a 14-day washout period, after which participants entered a 90-day control period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \>140 mmHg and/or DBP \>90 mmHg)
You may not be if
Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months